Latest News and Press Releases

– Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments – – Carmot will join the Roche Group as part of Roche’s Pharmaceuticals...

– Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D) – – A second mechanistic clinical trial is...

– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...

– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity and type 2 diabetes – – Phase 1b data for CT-868, a once-daily...

– Proceeds to support development of Carmot's broad clinical-stage metabolic pipeline including two Phase 2 trials of CT-388, a once weekly, dual GLP-1/GIP receptor modulator for obese adults with and...

– A presentation on 4-week weight loss data from CT-388, a once weekly, dual GLP-1/GIP receptor modulator being developed for obese patients with and without type 2 diabetes – – Two presentations on...